evaluation of movement disorders bryan yanaga, m.d. medical director bankers life and casualty

40
Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Upload: omarion-pilgreen

Post on 14-Dec-2015

216 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Evaluation of Movement Disorders

Bryan Yanaga, M.D.Medical Director

Bankers Life and Casualty

Page 2: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s Disease

Page 3: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s Disease

• What is it?

• What are the (early) symptoms?

• How is it treated?

• How do you differentiate (early) PD from a movement disorder that could be benign or reversible?

• Why this is important for underwriting and claims?

Page 4: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty
Page 5: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s Disease

• A gradually progressive degenerative disorder of the nervous system that affects movement.

Page 6: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s Disease

• Average age of onset: Late 50’s/Early 60’s

• 1.5x more common in men than women

• Incidence: 60,000 new cases per year

• Prevalence: 1.6 million in the USA

• Affects 1% of people over age 60

5% of people over age 80.

Page 7: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Neuropathology of Parkinson’s Disease

• Loss of pigmented dopaminergic neurons in the substantia nigra of the midbrain

Page 8: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Neurotransmission

From: Immunology and Cell Biology, 2012

Page 9: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Symptoms Associated with Parkinson’s Disease

Three cardinal signs:

• Tremor

• Rigidity

• Bradykinesia

• Postural instability

Page 10: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Evaluating Parkinson’s Disease

Tremor

• Insidious onset

• Gradual progression

• Begins in the hands

• Usually unilateral, can become bilateral

• Usually occurs at rest (Pill rolling)

Page 11: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Evaluating Parkinson’s Disease

Rigidity - Increased resistance to passive movement at a joint

• Smooth (lead pipe)

• Oscillating (cog wheeling)

Page 12: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Evaluating Parkinson’s Disease

Bradykinesia

• Slowness of movement

• Reduced spontaneous movements

• Decreased amplitude of movement

Page 13: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Underwriting Parkinson’s Disease

Examples of Bradykinesia

• Micrographia – Small handwriting• Hypomimia – Loss of facial expression• Decreased blink rate• Loss of hand dexterity • Slowness rising from a chair, turning in bed• Slow gait, smaller steps, lower cadence,

dragging of one leg

Page 14: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Treatment

Sinemet (levodopa/carbidopa)

• Levodopa is broken down to dopamine in the brain and peripheral circulation

• Peripheral dopamine causes nausea

• Carbidopa prevents peripheral conversion of levodopa to dopamine

• Allows for use of lower doses of levodopa

Page 15: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Prognosis (Before the introduction of Sinemet)

Time to severe disability or death:

• Within 5 years of onset - 25% of patients

• Within 10 years of onset - 65% of patients

• Within 15 years of onset - 89% of patients

Page 16: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Prognosis (After the introduction of Sinemet)

• 50% drop in mortality rate

Page 17: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Estimated life expectancy of Parkinson’s patients compared with

the UK population

Age Life Expectancy Average age at death

25-39 38 (49) 71 (82)

40-64 21 (31) 73 (83)

65+ 5 (9) 88 (91)

• Ishihara, LS, et.al., J Neurol Neurosurg Psychiatry 78(12): 1304-1309,2007.

Page 18: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Complications

With long-term use of Sinemet:

• Shortened duration of drug effectiveness

• Wider fluctuations in drug effectiveness (on-off phenomena)

• Dyskinesias (choreiform movements) occur at peak doses of levodopa

Page 19: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Complications

• Goal is to use the lowest dose of levodopa as possible

Page 20: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Treatment

Dopamine agonists

• Mirapex (pramipexole)

• Requip (ropinerole)

• Parlodel (bromocriptine)

• Bind to dopamine receptors in the brain and mimic the action of dopamine

Page 21: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty
Page 22: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Progression of Parkinson’s Disease

Unified Parkinson’s Disease Rating Scale (UPDRS)

• No medication needed • Good response to medications • Waning medication response • Unpredictable medication response• Dyskinesias• Severely Unpredictable Symptoms

Page 23: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Progression of Parkinson’s Disease

Unified Parkinson’s Disease Rating Scale (UPDRS)

• No medication needed. Patient with Newly Diagnosed Parkinson’s disease:• Good response to Medications: Symptoms are markedly reduced without

evidence of breakthrough symptoms between doses. Can last five years or longer on Sinemet.

• Waning medication response: Breakthrough symptoms begin to occur towards the end of each dose of medication. The dosage and/or frequency of medication must be increased.

• Unpredictable medication response. The breakthrough symptoms occur randomly. May be associated with On-Off Fluctuations: This stage is associated with more severe disability.

• Patient with Dyskinesias: These potentially disabling involuntary movements can occur when peak doses of medications are given. Surgical options for treatment can be considered.

• Severely Unpredictable Symptoms: May fluctuate between severe off state and severe dyskinesias despite careful medication management. Surgical options for treatment can be considered.

Page 24: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

The Goals of Underwriting

• Add good business to the books

• Keep bad business off the books.

Page 25: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Progression of Parkinson’s Disease

Unified Parkinson’s Disease Rating Scale (UPDRS)

• No medication needed • Good response to medications • Waning medication response • Unpredictable medication response• Dyskinesias• Severely Unpredictable Symptoms

Page 26: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

When is a tremor just a tremor?

Page 27: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Tremor – Differential Diagnosis

Neurological Disorders

• Parkinson’s disease

• Multiple sclerosis

• Stroke

• Traumatic brain injury

Page 28: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Tremor – Differential Diagnosis

Other Medical Conditions

• Chronic kidney disease

• Alcohol abuse or withdrawal

• Hyperthyroidism

• Liver failure

• Hypoglycemia

• Wilson’s disease (in younger patients)

Page 29: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Tremor – Differential Diagnosis

Deficiencies

• Thiamine

• Magnesium

• Vitamins (B1, B6, B12, E)

• Sleep

Page 30: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Essential Tremor

Benign

Risk factors

• Age

• Genetic mutation (autosomal dominant)

• Up to 20x more common than Parkinson’s

Page 31: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Essential Tremor• Insidious onset

• Can begin in one or both hands

• Usually bilateral and symmetrical

• Worse with movement (intention tremor)

• Can include a “yes” or “no” movement of the head

• Can be aggravated by stress, fatigue, caffeine, or extreme temperatures

Page 32: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Essential TremorComplications include the inability to:

• Hold a cup of water without spilling• Eat normally• Write• Shave or put on makeup• Talk (if the tongue or vocal chords are

affected)

Page 33: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Essential Tremor Test

                                                                                                                                     

Page 34: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s vs. Essential Tremor

Similarities:

• Insidious onset

• Usually begins in the hands/upper extremity

• Can be aggravated by stress

Page 35: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s vs. Essential Tremor

Differences:• Unilateral vs. bilateral• Most prominent at rest versus with activity• No involvement of the head and neck• Multiple progressive symptoms versus a

narrower range of symptoms

• Improvement with dopamine and dopaminergic agonists!

Page 36: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Underwriting Parkinson’s Disease

If the diagnosis is unclear (i.e. If the characteristic symptoms

of PD have yet to be revealed):

• Issue• Decline• Postpone

Request additional informationAllow time for development underlying pathology

Page 37: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Restless Legs Syndrome

• Discomfort in the legs, typically in the evening while sitting or lying down

• Relief when getting up and moving

• Symptoms worse at night

• Can begin at any age

• Usually worsens with age

Page 38: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Restless Legs Syndrome

Treatment

• Requip

• Mirapex

• Sinemet

Page 39: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Parkinson’s Disease

• What is it?

• What are the (early) symptoms?

• How is it treated?

• How do you differentiate (early) PD from a movement disorder that could be benign or reversible?

• Why this is important in underwriting and claims?

Page 40: Evaluation of Movement Disorders Bryan Yanaga, M.D. Medical Director Bankers Life and Casualty

Thank you.